Insider · CIK 0001296549
Arie Belldegrun
directorowner
Files at URGN (UroGen Pharma Ltd.), LBRX (LB PHARMACEUTICALS INC), ALLO (Allogene Therapeutics, Inc.), KRON (Kronos Bio, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 26, 2025 | URGN UroGen Pharma Ltd. | AGrant or award Stock Option (right ot buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Aug 27, 2025 |
| Jun 20, 2025 | KRON Kronos Bio, Inc. | UTender of shares Common Stockindirect: By Vida Ventures, LLC | -2,765,314 | $0.57 | $1.6M | 0 | Jun 20, 2025 |
| Jun 20, 2025 | KRON Kronos Bio, Inc. | UTender of shares Common Stockindirect: By Bellco Legacy II Trust | -679,575 | $0.57 | $387k | 0 | Jun 20, 2025 |
| Jun 20, 2025 | KRON Kronos Bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -20,600 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 20, 2025 | KRON Kronos Bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -34,000 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 20, 2025 | KRON Kronos Bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -34,000 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 20, 2025 | KRON Kronos Bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -34,000 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jan 24, 2025 | ALLO Allogene Therapeutics, Inc. | AGrant or award Common Stock | +369,957 | $0.00 | $0 | 2,236,816 | Jan 28, 2025 |
| Jan 24, 2025 | ALLO Allogene Therapeutics, Inc. | AGrant or award Stock Option (Right to buy)derivative | +1,307,927 | $0.00 | $0 | 1,307,927 | Jan 28, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.